Skip to main navigation
  • Contact Us
  • Careers
  • Press Releases
  • LinkedIn
Go to  Aquestive Therapeutics corporate website
  • About Us
    About Us
    • Executive Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Medicines
  • Pipeline
    Pipeline
    • Anaphylm™
    • Libervant®
  • Technologies
  • Services
  • Our Responsibilities
  • Investors
    Investors
      • Press Releases
      • Events & Presentations
      • Investor FAQs
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Quarterly Results
      • Corporate Fact Sheet
  • About Us
    • Executive Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Medicines
  • Pipeline
    • Anaphylm™
    • Libervant®
  • Technologies
  • Services
  • Our Responsibilities
  • Investors
    • Home
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Quarterly Results
  • Contact Us
  • Careers
  • Press Releases
  • LinkedIn
Breadcrumb
Home Investors

Creating Value by Overcoming Treatment Barriers

View previous quarters

Q2 2026 Latest Earnings

  • Earnings Release
  • Webcast
  • Presentation 1.9 MB
-
Today

Latest News

View all press releases
08.11.26
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read More
08.10.26
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Read More
07.29.26
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Read More

Events

View all events

Upcoming Events

There are no scheduled events at this time.

Past Events

08.12.26 8:00 AM EDT
Q2 2026 Aquestive Therapeutics, Inc. Earnings Conference Call
05.14.26 8:00 AM EDT
Q1 2026 Aquestive Therapeutics, Inc. Earnings Conference Call

Presentations

View all presentations
Anaphylm Human Factors and Clinical Study Supplemental Materials
Anaphylm Human Factors and Clinical Study Supplemental Materials
Corporate Presentation – February 2026 1.8 MB
Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB

Subscribe to our Email Alerts

Receive the latest posters, presentations, and data with our clinical trial portal.

  • Email Alerts
  • Investor Contact
  • Investor FAQs
  • RSS Feeds
Aquestive Therapeutics Logo
LinkedIn 

Advancing medicines to bring meaningful

improvement to patients' lives through

innovative science and delivery technologies

    • Investors
    • Press Releases
    • Careers
    • Pipeline
    • About Us
    • Medicines
    • Technologies
    • Services
    • Our Responsibilities
  • Cookie Settings
  • Privacy Policy
  • Contact Us
  • Privacy Notice for California Residents
  • Terms of Use
  • Do Not Sell or Share My Information

©  Aquestive Therapeutics, Inc. PharmFilm®, Libervant®, and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All rights reserved. All other registered trademarks referenced herein are the property of their respective owners.